1,152 material Form 8-K filings that 918 companies we cover made with the SEC in October 2025, each read and summarized by AI: what happened, the key figures, whether it reads positive or negative for shareholders, and how big a deal it is (impact 1-5). All of them were written later, when past filings were added: a selection, not every 8-K of the month (see the note below).
Kadant reported third quarter 2025 revenue of $271.6 million, flat with the prior year, while net income fell 12% to $27.7 million and diluted GAAP EPS fell to $2.35 from $2.68. The company raised its 2025 revenue guidance to $1.036 billion to $1.046 billion but cut its 2025 GAAP EPS guidance to $8.52 to $8.72, and kept adjusted EPS guidance at $9.05 to $9.25.
Q3 2025 revenue was $271.6 million, flat versus $271.6 million in Q3 2024; organic revenue fell 4%.
Q3 adjusted EBITDA fell 8% to $58.0 million, and adjusted EBITDA margin was 21.4% versus 23.3%.
2025 revenue guidance raised to $1.036 billion to $1.046 billion from $1.020 billion to $1.040 billion.
2025 GAAP EPS guidance cut to $8.52 to $8.72 from $8.89 to $9.09; adjusted EPS guidance maintained at $9.05 to $9.25.
Jack Henry & Associates reported $8.6 million of deconversion revenue for the fiscal first quarter ended September 30, 2025, and raised its full-year fiscal 2026 deconversion revenue estimate to $20 million. The filing covers only this revenue line, not total revenue or earnings, and the company says deconversion revenue is excluded from its non-GAAP revenue because it mainly arises when a client is acquired by another institution.
Fiscal Q1 2026 (quarter ended September 30, 2025) deconversion revenue was $8.6 million.
Full-year fiscal 2026 deconversion revenue estimate increased to $20 million.
Most deconversion revenue comes from clients being acquired by another financial institution, which ends their contract with Jack Henry.
Deconversion revenue is excluded from non-GAAP revenue in quarterly and annual earnings releases.
BrightSpring Health Services reported third-quarter 2025 revenue of $3,334 million, up 28.2% from a year earlier, and Adjusted EBITDA of $160 million, up 37.2%. The company raised its full-year 2025 revenue guidance and reiterated its Adjusted EBITDA guidance, which matters to shareholders because the headline sales and profit measures both improved.
Q3 2025 revenue was $3,334 million, up 28.2% from $2,601 million; continuing-operations net income was $37.5 million versus a net loss of $25.7 million a year earlier.
Adjusted EBITDA was $160 million, up 37.2% from $117 million.
2025 revenue guidance was raised to $12,500 million to $12,800 million; Adjusted EBITDA guidance of $605 million to $615 million was reiterated.
The planned sale of the Community Living business to Sevita is expected to close in Q1 2026.
W. P. Carey reported third-quarter 2025 revenues of $431.3 million, up 8.5% from a year earlier, and net income attributable to the company of $141.0 million, up 26.2%. The company raised and narrowed its full-year 2025 AFFO guidance to $4.93 to $4.99 per diluted share, citing higher expected investment volume, which matters to shareholders because AFFO is the company's main per-share earnings measure.
Q3 2025 revenues of $431.3 million, up 8.5% from $397.4 million in Q3 2024
Diluted EPS of $0.64 versus $0.51; AFFO of $1.25 per diluted share versus $1.18
2025 AFFO guidance raised and narrowed to $4.93 to $4.99 per diluted share, based on investment volume of $1.8 billion to $2.1 billion
Quarterly cash dividend of $0.910 per share, a 4.0% increase over the 2024 third quarter
EXL reported third-quarter 2025 results, with revenue up 12.2% year over year to $529.6 million and GAAP diluted EPS up 10.7% to $0.36. The company raised its full-year 2025 guidance for both revenue and adjusted diluted EPS, which points to stronger expected growth for shareholders, though operating income margin slipped to 14.4% from 14.7% a year earlier.
Q3 revenue of $529.6 million, up from $472.1 million in Q3 2024 (12.2% reported growth)
GAAP diluted EPS of $0.36 vs. $0.33 a year earlier; adjusted diluted EPS of $0.48 vs. $0.44
2025 revenue guidance raised to $2.07 billion to $2.08 billion; adjusted diluted EPS guidance raised to $1.88 to $1.92
Operating income margin of 14.4%, down from 14.7% in Q3 2024; conference call set for October 29, 2025 at 10:00 A.M. ET
Universal Health Services reported third-quarter 2025 net revenues up 13.4% to $4.495 billion and diluted EPS of $5.86, versus $3.80 a year earlier, and raised its full-year 2025 forecast for net revenues, Adjusted EBITDA net of NCI and Adjusted EPS-diluted. The board also added $1.5 billion to the stock repurchase authorization, bringing the available total to $1.759 billion, which matters to shareholders because it raises both the earnings outlook and the capacity for share buybacks.
Q3 2025 net income attributable to UHS was $373.0 million, or $5.86 per diluted share, versus $258.7 million, or $3.80, in Q3 2024
Q3 results included $90 million of pre-tax Medicaid reimbursements for Washington, D.C. and a $35 million pre-tax charge for professional and general liability reserves
2025 Adjusted EPS-diluted forecast raised to $21.50-$22.10 from $20.00-$21.00; net revenues forecast raised to $17.306-$17.445 billion
Board authorized a $1.5 billion increase to the stock repurchase program on October 27, 2025; 1.315 million shares repurchased in Q3 2025 for about $234.3 million
Repligen reported third-quarter 2025 revenue of $189 million, up 22% from $155 million a year earlier, and GAAP net income of $15 million versus a $1 million loss in the prior-year quarter. The company raised its full-year 2025 revenue guidance to $729 million to $737 million, and GAAP diluted EPS guidance is $0.82 to $0.85.
Q3 2025 revenue was $189 million, up 22% as reported and 18% organic, with no COVID-related revenue in either period.
GAAP diluted EPS was $0.26 versus a loss of $0.01 a year earlier; adjusted diluted EPS was $0.46 versus $0.43.
Full-year 2025 revenue guidance was increased to $729 million to $737 million, with GAAP diluted EPS guidance of $0.82 to $0.85.
Cash and cash equivalents were $749 million at September 30, 2025, compared with $757 million at December 31, 2024.
Incyte reported third-quarter 2025 total revenues of $1.37 billion, up 20% from a year earlier, and GAAP net income of $424.2 million, or $2.11 per diluted share, compared with $106.5 million, or $0.54 per diluted share, in the prior-year quarter. The company raised its full-year 2025 net product revenue guidance to $4.23-$4.32 billion, while reiterating its guidance for cost of product revenues, R&D and SG&A expenses.
Total revenues were $1.37 billion, up 20%; total net product revenues were $1.15 billion, up 19%.
GAAP diluted EPS was $2.11 versus $0.54 a year earlier; GAAP net income was $424.2 million versus $106.5 million.
Jakafi net product revenue rose 7% to $791 million; Opzelura rose 35% to $188 million.
Full-year 2025 net product revenue guidance was raised to $4.23-$4.32 billion, from the prior range that the filing lists for Jakafi and other oncology products.
A. O. Smith reported third-quarter 2025 net sales of $942.5 million, up 4%, and diluted EPS of $0.94, up 15% from $0.82 a year earlier. The company lowered its full-year 2025 sales outlook to flat to up 1% and narrowed its diluted EPS range to $3.70 to $3.85, with management citing China headwinds and weaker new home construction in North America, which matters to shareholders because the outlook is weaker even as recent results grew.
Q3 2025 net sales of $942.5 million, up 4%; net earnings of $132.0 million, up 10%; diluted EPS of $0.94, up 15%
Full-year 2025 consolidated sales now projected flat to up 1% versus 2024 actual of $3,818 million
Diluted EPS outlook narrowed to $3.70 to $3.85, with the midpoint lowered according to the CEO; 2024 diluted EPS was $3.63
China sales fell 12% in local currency in the quarter; board approved a 6% dividend increase on October 13, 2025
Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.
Briefs marked “Written later” were written in November 2026 for filings that were by then more than three weeks old, so months before mid-October 2026 hold a selection: every material 8-K of the past year for the 100 largest companies we cover and the last 15 important 8-Ks of every other one. Briefs the number check holds back are not shown or counted. Also: the last 45 days, briefs by company, A–Z and the live SEC filings wire.